Silver Oak Securities Incorporated Has $385,000 Stake in Pfizer Inc. (NYSE:PFE)

Silver Oak Securities Incorporated grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 51.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,368 shares of the biopharmaceutical company’s stock after acquiring an additional 4,522 shares during the quarter. Silver Oak Securities Incorporated’s holdings in Pfizer were worth $385,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the third quarter worth about $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the third quarter worth about $34,000. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the fourth quarter valued at approximately $36,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PFE shares. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.61 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The stock’s 50 day moving average is $26.88 and its 200-day moving average is $28.26. The firm has a market capitalization of $145.02 billion, a price-to-earnings ratio of 71.14, a PEG ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.14 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.56%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.